As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of ...

Vertex Pharma has chosen the three-drug combination it intends to submit for approval later this year for cystic fibrosis, in a bid to add another product to its stable. The US company has plumped ...

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.

Shares in Vertex have soared after the company announced that tens of thousands of cystic fibrosis (CF ... which big pharma buyers would need to offer as much as $60 billion to gain traction ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Equity markets have been seesawing for the past two weeks. Stocks fell hard after President Donald Trump announced his tariff ...

$1,600,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying ... General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes ...

Vertex Pharmaceuticals continues to develop therapies ... Vertex has been massively successful in developing medicines for cystic fibrosis (CF), a disease that affects internal organs.

Equity markets have been seesawing for the past two weeks. Stocks fell hard after President Donald Trump announced his tariff plans, then bounced back big once he said he would pause expanded ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Reshma Kewalramani, the Indian-origin CEO of US-based Vertex Pharmaceuticals, has been named on the list of "100 Most ...